Shares of Vaxart, Inc. (NASDAQ:VXRT - Get Free Report) crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.52 and traded as low as $0.40. Vaxart shares last traded at $0.44, with a volume of 1,691,828 shares changing hands.
Analysts Set New Price Targets
Several analysts have commented on the stock. Wall Street Zen raised shares of Vaxart to a "hold" rating in a research report on Thursday, May 22nd. B. Riley decreased their price target on shares of Vaxart from $2.50 to $2.00 and set a "buy" rating for the company in a research report on Thursday, March 27th.
Check Out Our Latest Stock Analysis on VXRT
Vaxart Price Performance
The stock has a market cap of $92.71 million, a price-to-earnings ratio of -1.50 and a beta of 1.14. The company's fifty day moving average price is $0.46 and its 200-day moving average price is $0.52.
Vaxart (NASDAQ:VXRT - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.07). Vaxart had a negative net margin of 122.63% and a negative return on equity of 91.89%. The firm had revenue of $20.88 million for the quarter, compared to the consensus estimate of $2.85 million. On average, sell-side analysts forecast that Vaxart, Inc. will post -0.39 earnings per share for the current fiscal year.
Insider Transactions at Vaxart
In other Vaxart news, insider Steven Lo purchased 100,000 shares of Vaxart stock in a transaction on Monday, May 19th. The stock was bought at an average cost of $0.49 per share, with a total value of $49,000.00. Following the transaction, the insider owned 100,000 shares of the company's stock, valued at $49,000. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 2.60% of the company's stock.
Institutional Investors Weigh In On Vaxart
Institutional investors have recently added to or reduced their stakes in the stock. Raymond James Financial Inc. purchased a new position in Vaxart in the 4th quarter valued at $129,000. Geode Capital Management LLC raised its holdings in shares of Vaxart by 2.3% during the 4th quarter. Geode Capital Management LLC now owns 2,601,139 shares of the biotechnology company's stock worth $1,723,000 after acquiring an additional 57,911 shares during the period. Invesco Ltd. raised its holdings in shares of Vaxart by 48.6% during the 4th quarter. Invesco Ltd. now owns 75,798 shares of the biotechnology company's stock worth $50,000 after acquiring an additional 24,803 shares during the period. Silverarc Capital Management LLC raised its holdings in shares of Vaxart by 7.8% during the 4th quarter. Silverarc Capital Management LLC now owns 1,077,782 shares of the biotechnology company's stock worth $714,000 after acquiring an additional 77,782 shares during the period. Finally, Bank of America Corp DE raised its holdings in shares of Vaxart by 10.8% during the 4th quarter. Bank of America Corp DE now owns 184,447 shares of the biotechnology company's stock worth $122,000 after acquiring an additional 17,942 shares during the period. Institutional investors and hedge funds own 18.05% of the company's stock.
About Vaxart
(
Get Free Report)
Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.
See Also
Before you consider Vaxart, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxart wasn't on the list.
While Vaxart currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
